Technical Analysis for EVG - Evgen Pharma Plc

Grade Last Price % Change Price Change
grade F 17.5 0.00% 0.00
EVG closed unchanged on Monday, July 15, 2019, on 16 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Down Flat
See historical EVG trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish 1.45%
Oversold Stochastic Weakness 1.45%
Hammer Candlestick Bullish 1.45%

Older signals for EVG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.
Chemistry Medicine Cancer Rtt Drug Development Pharmaceutical Products Breast Cancer Intensive Care Medicine Multiple Sclerosis Neurosurgery Organic Chemistry Prostate Cancer Stem Cells
Is EVG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 13.1
Average Volume 255,665
200-Day Moving Average 17.5709
50-Day Moving Average 19.182
20-Day Moving Average 17.95
10-Day Moving Average 17.5375
Average True Range 0.4569
ADX 29.9
+DI 18.7742
-DI 29.545
Chandelier Exit (Long, 3 ATRs ) 18.8793
Chandelier Exit (Short, 3 ATRs ) 18.3707
Upper Bollinger Band 19.2428
Lower Bollinger Band 16.6572
Percent B (%b) 0.33
BandWidth 14.404457
MACD Line -0.5288
MACD Signal Line -0.5304
MACD Histogram 0.0016
Fundamentals Value
Market Cap 12.75 Million
Num Shares 729 Thousand
EPS -62.34
Price-to-Earnings (P/E) Ratio -0.28
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.88
Resistance 3 (R3) 17.92 17.83 17.81
Resistance 2 (R2) 17.83 17.74 17.81 17.79
Resistance 1 (R1) 17.67 17.68 17.63 17.63 17.77
Pivot Point 17.58 17.58 17.56 17.56 17.58
Support 1 (S1) 17.42 17.49 17.38 17.38 17.23
Support 2 (S2) 17.33 17.43 17.31 17.21
Support 3 (S3) 17.17 17.33 17.19
Support 4 (S4) 17.13